Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a.

Chuan-Jue CuiJing-Lu JinLin-Na GuoJing SunNa-Qiong WuYuan-Lin GuoGeng LiuQian DongJian-Jun Li

Published in: Journal of translational medicine (2020)

The present study demonstrates that EGCG suppresses PCSK9 production by promoting nuclear FoxO3a, and reducing nuclear HNF1α, resulting in up-regulated LDLR expression and LDL uptake in hepatocytes. Thereby inhibiting liver and circulating PCSK9 levels, and ultimately lowering LDL-C levels.

Keyphrases

low density lipoprotein
signaling pathway
transcription factor
pi k akt
poor prognosis
nuclear factor
liver injury
immune response